STOCK TITAN

[Form 4] Procter & Gamble Company Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Jennifer L. Davis, an officer (CEO - Health Care) of Procter & Gamble Co. (PG), reported transactions on Form 4 showing grants and awards of company common stock and restricted stock units. On 08/18/2025 she acquired 21,518 shares via a stock award under the issuer's 2019 Stock and Incentive Compensation Plan at a reported price of $0, bringing her total beneficial ownership to 73,586.9326 shares (the total includes dividend equivalents settled in common stock). The filing also shows 15,401.6828 shares held indirectly by a retirement plan trustee and the acquisition of 24.9443 restricted stock units (RSUs) on 08/15/2025 that will convert to shares on retirement or be deferred into a compensation account. The document is signed by an attorney-in-fact on behalf of Ms. Davis on 08/20/2025.

Jennifer L. Davis, dirigente (CEO - Health Care) di Procter & Gamble Co. (PG), ha riportato operazioni nel Modulo 4 relative a attribuzioni e assegnazioni di azioni ordinarie della società e di unità azionarie vincolate (RSU). Il 18/08/2025 ha acquisito 21.518 azioni tramite un premio in azioni previsto dal Piano di Azioni e Incentivi 2019 dell'emittente, a un prezzo dichiarato di $0, portando la sua partecipazione beneficiaria complessiva a 73.586,9326 azioni (il totale include equivalenti di dividendi corrisposti in azioni ordinarie). Il deposito indica inoltre 15.401,6828 azioni detenute indirettamente da un fiduciario del piano pensionistico e l'acquisizione di 24,9443 unità azionarie vincolate (RSU) il 15/08/2025, che si convertiranno in azioni al momento del pensionamento o potranno essere differite in un conto di compensazione. Il documento è firmato da un procuratore in data 20/08/2025 per conto della Sig.ra Davis.

Jennifer L. Davis, ejecutiva (CEO - Health Care) de Procter & Gamble Co. (PG), informó transacciones en el Formulario 4 que muestran concesiones y adjudicaciones de acciones ordinarias de la compañía y unidades restringidas de acciones. El 18/08/2025 adquirió 21,518 acciones mediante una adjudicación de acciones en virtud del Plan de Acciones e Incentivos 2019 del emisor, a un precio declarado de $0, elevando su titularidad beneficiaria total a 73,586.9326 acciones (el total incluye equivalentes de dividendos liquidados en acciones ordinarias). La presentación también muestra 15,401.6828 acciones mantenidas indirectamente por un fideicomisario del plan de retiro y la adquisición de 24.9443 unidades restringidas de acciones (RSU) el 15/08/2025, que se convertirán en acciones al jubilarse o podrán diferirse en una cuenta de compensación. El documento está firmado por un apoderado el 20/08/2025 en nombre de la Sra. Davis.

Jennifer L. Davis, Procter & Gamble Co.(PG)의 임원(CEO - Health Care)은 Form 4에 회사 보통주 및 제한부 주식 단위(RSU)의 부여와 수령 내역을 신고했습니다. 2025/08/18에 발행사의 2019년 주식 및 인센티브 보상 플랜에 따른 주식 수여로 21,518주를 취득했으며, 신고 가격은 $0로 총 실질 보유지분은 73,586.9326주가 되었습니다(총액에는 보통주로 정산된 배당 등가물이 포함됨). 서류에는 또한 퇴직연금 수탁자가 15,401.6828주를 간접 보유하고 있고, 2025/08/15에 24.9443개의 제한부 주식 단위(RSU)를 취득했으며 이는 퇴직 시 주식으로 전환되거나 보상 계좌로 이연될 수 있다고 기재되어 있습니다. 문서는 2025/08/20에 Davis 씨를 대리한 위임대리인이 서명했습니다.

Jennifer L. Davis, dirigeante (CEO - Health Care) de Procter & Gamble Co. (PG), a déclaré des opérations sur le formulaire 4 faisant état d’attributions d’actions ordinaires de la société et d’unités d’actions restreintes (RSU). Le 18/08/2025, elle a acquis 21 518 actions via une attribution d’actions au titre du Plan d’Actions et d’Incitations 2019 de l’émetteur, au prix déclaré de 0 $, portant sa détention bénéficiaire totale à 73 586,9326 actions (le total inclut les équivalents de dividendes réglés en actions ordinaires). Le dépôt indique également 15 401,6828 actions détenues indirectement par un fiduciaire du régime de retraite et l’acquisition de 24,9443 unités d’actions restreintes (RSU) le 15/08/2025, qui seront converties en actions au départ à la retraite ou différées sur un compte de rémunération. Le document est signé le 20/08/2025 par un mandataire agissant au nom de Mme Davis.

Jennifer L. Davis, Geschäftsführerin (CEO - Health Care) von Procter & Gamble Co. (PG), meldete Transaktionen im Formular 4, die Zuteilungen und Gewährungen von Stammaktien des Unternehmens sowie Restricted Stock Units (RSU) ausweisen. Am 18.08.2025 erwarb sie 21.518 Aktien durch eine Aktienzuteilung gemäß dem Aktien- und Incentive-Plan 2019 des Emittenten zu einem gemeldeten Preis von $0 und erhöhte damit ihr gesamtes wirtschaftliches Eigentum auf 73.586,9326 Aktien (in der Summe sind in Stammaktien abgewickelte Dividendenäquivalente enthalten). Die Einreichung zeigt außerdem 15.401,6828 Aktien, die indirekt von einem Treuhänder eines Rentenplans gehalten werden, sowie den Erwerb von 24,9443 Restricted Stock Units (RSU) am 15.08.2025, die bei Ruhestand in Aktien umgewandelt oder in ein Vergütungskonto aufgeschoben werden können. Das Dokument ist am 20.08.2025 von einem Bevollmächtigten im Namen von Frau Davis unterzeichnet worden.

Positive
  • Insider acquisition disclosed: Officer acquired 21,518 shares under the company stock plan, increasing reported beneficial ownership to 73,586.9326 shares.
  • Retirement plan holdings identified: 15,401.6828 shares held indirectly by a retirement plan trustee, clarifying indirect ownership.
  • Dividend equivalents settled: Filing confirms dividend equivalents were granted in the form of RSUs and included in the total share count.
  • Clear Section 16 compliance: Form 4 filed and signed by attorney-in-fact, providing required insider transparency.
Negative
  • None.

Insights

TL;DR: Officer received compensation awards settled in stock and holds indirect retirement-plan shares; routine insider reporting with governance transparency.

The Form 4 discloses non-derivative stock awards and RSUs granted under the company's compensation and retirement plans. These awards were recorded at a $0 price, consistent with typical stock-based compensation and dividend-equivalent settlement practices. The filing separates direct beneficial ownership from indirect retirement-plan holdings, which is important for clarity on voting and disposition rights. The data are procedural and reflect standard governance disclosure rather than any operational change.

TL;DR: Reported grant sizes are modest and align with typical executive compensation mechanics; no market-moving amounts disclosed.

The reported acquisition of 21,518 shares and 24.9443 RSUs, plus 15,401.6828 indirect shares, represent grant and retirement-plan settlements rather than open-market purchases or disposals. The filing documents the mechanics: grants under the 2019 plan and dividend-equivalent RSUs for retirement benefits. From a securities perspective, these are routine Section 16 disclosures required to maintain transparency on insider holdings.

Jennifer L. Davis, dirigente (CEO - Health Care) di Procter & Gamble Co. (PG), ha riportato operazioni nel Modulo 4 relative a attribuzioni e assegnazioni di azioni ordinarie della società e di unità azionarie vincolate (RSU). Il 18/08/2025 ha acquisito 21.518 azioni tramite un premio in azioni previsto dal Piano di Azioni e Incentivi 2019 dell'emittente, a un prezzo dichiarato di $0, portando la sua partecipazione beneficiaria complessiva a 73.586,9326 azioni (il totale include equivalenti di dividendi corrisposti in azioni ordinarie). Il deposito indica inoltre 15.401,6828 azioni detenute indirettamente da un fiduciario del piano pensionistico e l'acquisizione di 24,9443 unità azionarie vincolate (RSU) il 15/08/2025, che si convertiranno in azioni al momento del pensionamento o potranno essere differite in un conto di compensazione. Il documento è firmato da un procuratore in data 20/08/2025 per conto della Sig.ra Davis.

Jennifer L. Davis, ejecutiva (CEO - Health Care) de Procter & Gamble Co. (PG), informó transacciones en el Formulario 4 que muestran concesiones y adjudicaciones de acciones ordinarias de la compañía y unidades restringidas de acciones. El 18/08/2025 adquirió 21,518 acciones mediante una adjudicación de acciones en virtud del Plan de Acciones e Incentivos 2019 del emisor, a un precio declarado de $0, elevando su titularidad beneficiaria total a 73,586.9326 acciones (el total incluye equivalentes de dividendos liquidados en acciones ordinarias). La presentación también muestra 15,401.6828 acciones mantenidas indirectamente por un fideicomisario del plan de retiro y la adquisición de 24.9443 unidades restringidas de acciones (RSU) el 15/08/2025, que se convertirán en acciones al jubilarse o podrán diferirse en una cuenta de compensación. El documento está firmado por un apoderado el 20/08/2025 en nombre de la Sra. Davis.

Jennifer L. Davis, Procter & Gamble Co.(PG)의 임원(CEO - Health Care)은 Form 4에 회사 보통주 및 제한부 주식 단위(RSU)의 부여와 수령 내역을 신고했습니다. 2025/08/18에 발행사의 2019년 주식 및 인센티브 보상 플랜에 따른 주식 수여로 21,518주를 취득했으며, 신고 가격은 $0로 총 실질 보유지분은 73,586.9326주가 되었습니다(총액에는 보통주로 정산된 배당 등가물이 포함됨). 서류에는 또한 퇴직연금 수탁자가 15,401.6828주를 간접 보유하고 있고, 2025/08/15에 24.9443개의 제한부 주식 단위(RSU)를 취득했으며 이는 퇴직 시 주식으로 전환되거나 보상 계좌로 이연될 수 있다고 기재되어 있습니다. 문서는 2025/08/20에 Davis 씨를 대리한 위임대리인이 서명했습니다.

Jennifer L. Davis, dirigeante (CEO - Health Care) de Procter & Gamble Co. (PG), a déclaré des opérations sur le formulaire 4 faisant état d’attributions d’actions ordinaires de la société et d’unités d’actions restreintes (RSU). Le 18/08/2025, elle a acquis 21 518 actions via une attribution d’actions au titre du Plan d’Actions et d’Incitations 2019 de l’émetteur, au prix déclaré de 0 $, portant sa détention bénéficiaire totale à 73 586,9326 actions (le total inclut les équivalents de dividendes réglés en actions ordinaires). Le dépôt indique également 15 401,6828 actions détenues indirectement par un fiduciaire du régime de retraite et l’acquisition de 24,9443 unités d’actions restreintes (RSU) le 15/08/2025, qui seront converties en actions au départ à la retraite ou différées sur un compte de rémunération. Le document est signé le 20/08/2025 par un mandataire agissant au nom de Mme Davis.

Jennifer L. Davis, Geschäftsführerin (CEO - Health Care) von Procter & Gamble Co. (PG), meldete Transaktionen im Formular 4, die Zuteilungen und Gewährungen von Stammaktien des Unternehmens sowie Restricted Stock Units (RSU) ausweisen. Am 18.08.2025 erwarb sie 21.518 Aktien durch eine Aktienzuteilung gemäß dem Aktien- und Incentive-Plan 2019 des Emittenten zu einem gemeldeten Preis von $0 und erhöhte damit ihr gesamtes wirtschaftliches Eigentum auf 73.586,9326 Aktien (in der Summe sind in Stammaktien abgewickelte Dividendenäquivalente enthalten). Die Einreichung zeigt außerdem 15.401,6828 Aktien, die indirekt von einem Treuhänder eines Rentenplans gehalten werden, sowie den Erwerb von 24,9443 Restricted Stock Units (RSU) am 15.08.2025, die bei Ruhestand in Aktien umgewandelt oder in ein Vergütungskonto aufgeschoben werden können. Das Dokument ist am 20.08.2025 von einem Bevollmächtigten im Namen von Frau Davis unterzeichnet worden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis Jennifer L.

(Last) (First) (Middle)
1 PROCTER & GAMBLE PLAZA

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PROCTER & GAMBLE Co [ PG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Health Care
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/18/2025 A 21,518 A $0(1) 73,586.9326(2) D
Common Stock 15,401.6828 I By Retirement Plan Trustee
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (3) 08/15/2025 A V 24.9443 (4) (4) Common Stock 24.9443 $0 228.7027 D
Explanation of Responses:
1. Stock award pursuant to issuer's 2019 Stock and Incentive Compensation Plan.
2. Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock.
3. Dividend equivalents in the form of Restricted Stock Units (RSUs) previously awarded pursuant to issuer's retirement program. All such RSUs represent a contingent right to receive Procter & Gamble common stock.
4. These units will deliver in shares on retirement from the company, unless delivery is deferred or such shares are contributed to reporting person's deferred compensation account.
/s/ Wednesday Shipp, attorney-in-fact for Jennifer L. Davis 08/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Procter & Gamble

NYSE:PG

PG Rankings

PG Latest News

PG Latest SEC Filings

PG Stock Data

373.63B
2.34B
0.06%
70.04%
0.72%
Household & Personal Products
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Link
United States
CINCINNATI